We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > TriTAC

News List

Harpoon Therapeutics Granted Orphan Drug Designation for Multiple Myeloma Treatment americanpharmaceuticalreview
January 20, 2021
Harpoon Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for HPN217 for the treatment of multiple myeloma. HPN217, a tri-specific T cell activating recombinant protein construct (TriTAC®) targets ...
Harpoon Therapeutics Doses First Patient with Anti-DLL3 T Cell Engager for Lung Cancer americanpharmaceuticalreview
January 11, 2021
Harpoon Therapeutics announced the first patient has been dosed with HPN328, a delta like ligand 3- (DLL3) targeting TriTAC®, in a Phase 1/2 clinical trial as an investigational treatment of small cell lung cancer (SCLC) and other tumors associated ...